Table 3.
Maternal outcomes at delivery.
| Study | Buprenorphine-Naloxone Group Outcomes |
Significant Differences |
|---|---|---|
| Debelak [12] |
Bup-nlx dose 1: 8–16 mg UDS pos for illicit drugs 2: 0% |
No comparison group |
| Dooley [17] |
Quit illicit opioid use: 80% Reduced illicit opioid use: 10% |
Higher rate of illicit opioid cessation in bup-nlx group compared to illicit opioid group * |
| Gawronski [15] |
Mean bup-nlx dose: 20 mg UDS pos for illicit drugs: 47% |
Higher rate of pos UDS in bup-nlx group compared to methadone group * |
| Jumah [18] |
Mean bup-nlx dose: 8 mg Prenatal opioid use: 18% |
Lower rate of daily prenatal opioid use in bup-nlx group compared to illicit opioid group * |
| Mullins [14] |
Median bup-nlx dose: 12 mg UDS pos for illicit drugs: 55% |
Lower median dose in bup-nlx group compared to bup-monoproduct group * |
| Nguyen [13] |
UDS pos for illicit drugs: 35% | No comparison group |
| Wiegand [16] |
Mean bup-nlx dose: 14 mg UDS pos for illicit drugs: 20% |
No significant differences |
1 Mean bup-nlx dose: mean buprenorphine-naloxone dose at delivery. 2 UDS pos for illicit drugs: urine drug screen positive for illicit drugs at delivery. * indicates statistical difference (p < 0.05).